Commit(R) introduces cappuccino-flavored lozenge to help soothe nicotine cravings PITTSBURGH, Nov. 17
PITTSBURGH, Nov. 17 /PRNewswire/ -- A new survey shows half of all smokers
regularly drink coffee and smoke at the same time.(1) While smokers may say
coffee drinking goes hand in hand with their cigarette, many are unaware that
smoking actually affects the way their body processes caffeine.(1) A recent
survey conducted by the marketers of Commit(R) Cappuccino shows that while
smokers drink almost twice as much coffee as nonsmokers, an overwhelming
86 percent surveyed are unaware that they may need to cut back their caffeine
intake when trying to quit.(1)
Studies show that smoking causes smokers to metabolize caffeine faster.(2)
As a result, smokers need to ingest more caffeine to get the same effects of
nonsmokers.(2) So when a smoker tries to quit, they may end up with more
caffeine in their system, and may need to reduce their caffeine intake when
trying to quit. In fact, the survey shows that fewer than one in ten smokers
(9 percent) know how smoking affects the way their body processes caffeine.(1)
Additionally, about one-third of smokers (about 32 percent) do not know that
too much caffeine in the blood can be harmful.(1)
According to the survey, almost three quarters (71 percent) of smokers
enjoy the flavor of coffee.(1) With the introduction of Commit's cappuccino-
flavored lozenge, smokers now have a new flavor of lozenge to conquer their
addiction to cigarettes. Like other Commit flavors, Commit Cappuccino
provides low, safe doses of therapeutic nicotine to calm withdrawal symptoms
in a new, smooth, coffee flavor.(3) The Commit Cappuccino lozenge helps
smokers quit successfully by calming nicotine cravings, as well as soothing
other withdrawal symptoms such as anxiety and irritability, allowing smokers
to wean off nicotine gradually and safely.(4)
"It is important smokers understand that they don't need to give up coffee
when trying to quit, but by drinking less coffee, they may help their body
adjust to life without cigarettes, and avoid caffeine side effects," said Saul
Shiffman, PhD, researcher and professor in the departments of psychology and
pharmaceutical science at the University of Pittsburgh and GlaxoSmithKline
Consumer Healthcare spokesperson. "The tie between smoking and coffee-
drinking is clear and the new Commit Cappuccino lozenge is a great option to
help a smoker quit in a safe, effective way. It calms nicotine cravings and
withdrawal symptoms, while giving smokers the coffee flavor they enjoy without
the caffeine."
Other Survey Findings:
-- Among the adults surveyed, smokers drink an average of 2.8 cups of
coffee per day, while nonsmokers drink 1.5 cups.(1)
-- Almost half (about 43 percent) of smokers report that drinking coffee
makes them want to have a cigarette.(1)
The recent 2008 PHS Smoking Cessation Guideline identified the Commit
nicotine lozenge as a first-line treatment that can reliably increase long-
term smoking abstinence.(5) The Commit lozenge is approved by the U.S. Food
and Drug Administration (FDA) to help relieve withdrawal symptoms and cravings
associated with quitting smoking and uses a unique dosage selector so that
smokers can choose the strength that's right for them.(5) For more
information, smokers can visit Commitlozenge.com. Visitors can also request a
free 24-count of Commit Cappuccino to get their quit attempt started.
About the Commit Lozenge
Commit Cappuccino joins three other lozenge offerings -- Original, Mint
and Cherry -- in the Commit family, giving smokers another effective
therapeutic nicotine option for smoking cessation. Commit is approved by the
FDA to help control craving associated with quitting smoking. Commit has a
unique dosage selector based on how soon smokers smoke their first cigarette
in the morning, so they can choose the strength that's right for them. Commit
comes in different strengths -- 2 mg or 4 mg -- to be used depending on how
soon a smoker has his first cigarette in the morning. The 2 mg dosage is for
smokers who usually have their first cigarette more than thirty minutes after
waking up. The 4 mg dosage is for smokers who usually have their first
cigarette within thirty minutes of waking up. The Commit lozenge helps people
stop smoking by providing low, safe doses of therapeutic nicotine to ease
withdrawal from cigarettes.
About the Survey
Richard Day Research conducted the Internet survey including 1,095 U.S.
adults, including 322 smokers, age 18 and older, selected to reflect the adult
U.S. population. The survey was fielded in July 2008 through an online panel.
The survey was conducted on behalf of GlaxoSmithKline Consumer Healthcare, the
industry leader in smoking cessation.
About GlaxoSmithKline Consumer Healthcare
GlaxoSmithKline (GSK) Consumer Healthcare is one of the world's largest
over-the-counter consumer healthcare products companies. GSK offers the
widest range of proven TN products available, products which can significantly
improve a smoker's chance of quitting successfully and have helped millions of
people quit smoking. In addition, GSK offers several resources and support
services designed specifically to help smokers and nonsmokers understand and
address the two components to smoking cessation: nicotine addiction and habit
change. Its more than 30 well-known brands include the leading smoking
cessation products, Nicorette(R), NicoDerm(R) CQ and Commit(R) as well as many
medicine cabinet staples, including Abreva(R), alli(R), Aquafresh(R),
Sensodyne(R), Tums(R) and Breathe Right(R), trademarks owned and/or licensed
to GlaxoSmithKline Group of Companies.
About GlaxoSmithKline
GlaxoSmithKline is one of the world's leading research-based
pharmaceutical and consumer healthcare companies. GlaxoSmithKline is
committed to improving the quality of human life by enabling people to do
more, feel better and live longer.
1. Survey of 1,095 U.S. adults, Richard Day Research. July 2008.
2. Cone EJ. Nicotine and Tobacco. Handbook of Drug Interactions.
2004: 3.2.7.
3. FDA labeling on Commit Cappuccino box. 2008.
4. Henningfield JE. Nicotine medications for smoking cessation.
New England Journal of Medicine. 1995;333:1196-1203.
5. Fiore MC, Jaen CR, Baker TB, et al. Treating Tobacco Use and
Dependence: 2008 Update. Clinical Practice Guideline. Rockville, MD:
U.S. Department of Health and Human Services. Public Health Service.
May 2008.
Contacts: Teresa Calanni, GolinHarris
312-729-4229
tcalanni@golinharris.com
Jennifer May, GlaxoSmithKline Consumer Healthcare
412-200-3729
jennifer.l.may@gsk.com
SOURCE GlaxoSmithKline (GSK) Consumer Healthcare
